Аңдатпа
Background: Preventing the accumulation of organ damage is a primary objective in the treatment of Behçet's Syndrome (BS). The PROBE study, which stands for PROspective Multiethnic Validation of the BEhçet's Syndrome Overall Damage Index (BODI), aims to validate the BODI in a diverse and ethnically varied group of BS patients. Objectives: To assess the prevalence, extent, and determinants of organ damage accrual in the PROBE cohort over 12 months of follow-up. Methods: 894 consecutive BS patients from 11 Countries clustered in 5 geographic areas - Europe (EU, n 323), Middle East (ME, n 259), North Africa (NA, n 237), Central Asia (CA, n 33), America (AM, 42) - underwent a 12 ± 5 months follow-up visit. The original cohort consisted of 970 patients, finally reduced to 894 due to 76 patients lacking 1-year visit (68 patients lost to follow-up and 8 patients dead over time). Attrition analysis showed no major differences between patients included in the analysis and those excluded (not reported in this abstract). Demographics, previous and ongoing medication, Behcet's Disease Current Activity Form (BDCAF) score, Physician (PGA) and Patient Global Assessment (PtGA) of disease activity, disease relapse (defined by any treatment change due to increased disease activity), and the BODI score were recorded. Damage accrual was defined as any increase ≥ 1 in the BODI score between baseline and follow-up visit (Δ-BODI). Logistic regression models were built to identify factors associated with BODI damage accrual. Results: The mean age (standard deviation) at enrolment and the disease duration were 41.1 (12.7) and 12.1 (9.8) years, respectively; 493 (55.1 %) patients were males. At baseline, the mean BODI score was 1.9 (2.2), with 569 (63.6 %) patients having a BODI ≥ 1. During the 12 months of follow-up, the mean BODI score increased to 2.1 (2.3), and 128 (14.3 %) patients had an increase in the BODI score of at least 1 point (mean increase of 1.5 points). The distribution of BODI damage accrual according to different domains is reported in Figure 1. Overall, 193 new BODI items of damage were recorded, and 605 (67.7 %) patients had a BODI ≥ 1 at the end of follow-up. Factors independently associated with increased BODI score were ocular involvement (OR 2.33, 95%CI 1.37-3.95, p = 0.002), a higher dose of prednisone equivalent at enrolment (OR 1.03 per mg/day, 95%CI 1.02-1.05, p < 0.001), and occurrence of disease relapse (OR 1.98, 95%CI 1.20-3.23, p = 0.007). The association between damage accumulation and geographic origin was not confirmed (Table 1). With reference to the 8 deceased patients, cause of death was aneurism rupture in 3 patients (2 pulmonary artery and 1 aorta), malignancy in 2, septic shock, respiratory failure and unknown in 1 each. Figure 1 Conclusion: The BODI demonstrated to capture organ damage in a wide and ethnically heterogeneous cohort. Ocular manifestations, relapse of disease activity, and a higher exposure to glucocorticoids proved to be major determinants of damage accumulation in BS. REFERENCES: NIL . Acknowledgements: NIL . Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.